Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $481.56M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.12M
Average 0.17M
MNPR Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How MNPR compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 32.2% | — | -34446.7 pp | |
| LTM Sep 2026 | 16.3% | +63.4 pp | -106.7 pp | |
| LTM Mar 2026 | -44.8% | -8.2 pp | +29.9 pp | |
| LTM Jun 2026 | -155.6% | -46.5 pp | -39.7 pp | |
| LTM Mar 2026 | -173.0% | +24.6 pp | -100.4 pp | |
| LTM Mar 2026 | -345.0% | +445.1 pp | +477.7 pp | |
| FY2025 | -1764.5% | -1372.5 pp | -1663.8 pp | |
| FY2025 | -3060.0% | +180.4 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding MNPR) | -164.3% | +24.6 pp | -100.4 pp | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.49M | 7.59M | 5.6M | 13.01M | 9.9B |
| Selling, General & Admin | 2.63M | 2.95M | 3.23M | 3.16M | 6.8B |
| Operating Expenses | 9.13M | 10.54M | 8.83M | 16.16M | 16.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.13M) | (10.54M) | (8.83M) | (16.16M) | (16.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24.02K | 21.24K | 429.04K | 404.02K | 2.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 24.02K | 21.24K | 429.04K | 575.3K | 2.99M |
| Income Before Tax | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| EPS (Diluted) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| Weighted Avg Shares | 12.47M | 12.72M | 14.51M | 11.44M | 7.41M |
| Weighted Avg Shares (Diluted) | 12.47M | 12.72M | 14.51M | 11.48M | 7.41M |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$71.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.